[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Butler Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":245},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,74,95,127,150,173,195,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100549319","tdcs-to-decrease-opioid-relapse-uh3-100549319",false,"NCT06432465","tDCS to Decrease Opioid Relapse (UH3)","Inclusion Criteria:\n\n1. current opioid dependence\n2. between 21-60 years of age\n3. recent initiation of buprenorphine or methadone (≤90 days)\n4. enrolled in Butler Hospital's Alcohol and Drug Inpatient Unit, Alcohol and Drug Partial Hospital Treatment Program, Intensive Outpatient Services, or Outpatient Services at Butler Hospital OR receive opioid-treatment services in the community.\n\nExclusion Criteria:\n\n1. current diagnosis of organic brain disorder (e.g., Parkinson's disease, Huntington's disease, multiple sclerosis, intracranial mass\u002Finfection, hydrocephalus)\n2. bipolar, schizophrenia, schizoaffective, or schizophreniform disorder, or current psychosis associated with any disorder\n3. current suicidality\n4. evidence of significant neurocognitive dysfunction\n5. conditions associated with heightened tDCS risks, e.g., seizure disorder, nonremovable intracranial metal objects (other than dental fillings and dental implants), skin disease or active lesions on the scalp, migraine\u002Fother headache disorder with significant active symptoms, traumatic brain injury or skull fracture within the past year, any implanted medical devices or device components that can interact with electromagnetic fields or are controlled by physiological signals\n6. probation\u002Fparole requirements or an upcoming move that might interfere with protocol participation\n7. planning to terminate buprenorphine or methadone in less than 3 months\n8. current pregnancy or plan to become pregnant in the next month.","ALL","21 Years","60 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.",[26],"Opioid Use Disorder",[28,29,30,31,32],"opioid craving","buprenorphine","methadone","EEG","transcranial direct current stimulation","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2024-04-17",{"date":41,"type":20},"2026-12-31",{"name":43,"class":44},"Butler Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100629528","teenthrive-2-treatments-for-improving-mood-in-teens-100629528","NCT07475845","Teenthrive 2: Treatments for Improving Mood in Teens","Set A Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 10 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia;\n2. Be aged 12-18;\n3. Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider);\n4. Be able to read and write in English;\n5. Provide consent\u002Fassent appropriate to age;\n6. Be able to attend group session times:\n7. Have access to a private space once per week that is suitable for synchronous intervention sessions.\n\nSet A Exclusion criteria: Adolescents will be excluded if they:\n\n1. Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia;\n2. Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation;\n3. Have severe depression (QIDS-A-CR score \\> = 16);\n4. Have moderate or high risk for suicide (Response of \"yes\" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months).\n5. Have suicide ideation (Response of \"yes\" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy)\n6. Are pregnant;\n7. Are currently (past 4 weeks) engaged in yoga classes or in gCBT;\n8. Have had substantive changes in other psychiatric treatment in the previous 4 weeks (e.g., started a new depression medication; stopped or started attending psychotherapy).\n9. Have a sibling or other household member active in a study intervention (for this study) at the same time.\n\nSet B Eligibility criteria\n\nParticipants who are not eligible for Set A may be enrolled in Phase 2 Set B, such that they will be eligible to attend classes but their data will not be considered in our main analyses.\n\nSet B Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 6 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia;\n2. Be aged 12-18;\n3. Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider);\n4. Be able to read and write in English;\n5. Provide consent\u002Fassent appropriate to age;\n6. Be able to attend group session times:\n7. Have access to a private space once per week that is suitable for synchronous intervention sessions.\n\nSet B Exclusion criteria: Adolescents will be excluded if they:\n\n1. Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia;\n2. Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation;\n3. Have severe depression (QIDS-A-CR score \\> = 16);\n4. Have moderate or high risk for suicide (Response of \"yes\" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months).\n5. Have suicide ideation (Response of \"yes\" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy)\n6. Are pregnant;\n7. Are currently (past 4 weeks) engaged in yoga classes or in gCBT;\n8. Have a sibling or other household member active in a study intervention (for this study) at the same time.","12 Years","18 Years",{"count":55,"type":20},96,[23],"In this study, we will conduct a pilot RCT of a yoga-based intervention (YBI) vs. group cognitive-behavioral therapy (gCBT) at two sites. We will recruit 48 adolescent participants each in Columbus, OH and Boston, MA (96 total). We have a priori targets for indices of feasibility and acceptability, including recruitment rate, retention for assessments, class attendance, interventionist fidelity to manuals, and participant satisfaction. We hypothesize that we will meet these metrics at both sites.",[59],"Depression in Adolescence",[61,62,63,64],"depression","yoga","cognitive-behavioral therapy","adolescent","2026-06-08",{"date":67,"type":37},"2026-06-10",{"date":69,"type":20},"2026-06-15",{"date":71,"type":20},"2027-12",{"name":43,"class":44},2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100624052","video-intervention-for-older-adults-with-chronic-pain-100624052","NCT07404618","Video Intervention for Older Adults With Chronic Pain","Development and Preliminary Testing of a Peer Narrative Video Intervention for Older Adults With Chronic Pain","Inclusion Criteria:\n\n1. Chronic MSK pain. Consistent with existing guidance, the experience of pain must be present most days of the week over the past 3 months, of at least moderate intensity.\n2. Pain interferes with everyday activities.\n3. Age 55 or older.\n4. Proficiency in English sufficient to engage in informed consent and understand assessments and materials.\n5. Reliable internet access.\n\nExclusion Criteria:\n\n1. Currently receiving acceptance\u002Fmindfulness or similar psychotherapy for chronic pain management.\n2. Current severe substance use problems.\n3. Cognitive impairment that would interfere with a person's capacity to complete the study.","55 Years",{"count":19,"type":20},[23],"Chronic musculoskeletal (MSK) pain, which includes spinal pain, osteoarthritis, and fibromyalgia, is a common and costly problem for older adults and is associated with decreased quality of life. In this project, investigators propose to create Reclaim Your Day (RYD), which will consist of 6, 30-min weekly video episodes highlighting patients' inspiring and illustrative experiences living with chronic pain in order to teach current patients with chronic MSK pain how to apply ACT's evidence-based strategies. INvestigators will conduct a pilot RCT (n=100) of older adults with chronic MSK pain. All participants will receive an introductory pain education video. Participants will be randomized to receive either RYD or a comparison intervention (health education videos). Investigators will examine RYD feasibility and acceptability as well as changes over time in outcomes (pain interference, depression, quality of life) and putative mediators.",[86,87,88],"Chronic Pain","Musculoskeletal Pain","Older Adults With Chronic Pain",{"date":67,"type":37},{"date":91,"type":37},"2026-05-01",{"date":93,"type":20},"2027-08-31",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":103,"minAge":53,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100636861","transcranial-magnetic-stimulation-as-a-treatment-for-postpartum-obsessive-compulsive-disorder-100636861","NCT07571187","Transcranial Magnetic Stimulation as a Treatment for Postpartum Obsessive Compulsive Disorder","Continuous Theta Burst Treatment as a Novel Treatment for Postpartum Obsessive Compulsive Disorder","Project MOM","Inclusion Criteria:\n\n1. Age 18-45\n2. Diagnosis of OCD defined by DSM-V criteria with problematic symptoms in the 12 months following childbirth\n3. YBOCS ≥16\n4. Either currently taking OCD medications at a stable dose for 8 weeks or unmedicated\n5. Concurrent psychotherapy (exposure and response prevention therapy) will be allowed if it was initiated 8 weeks or more before study entry and continues regularly throughout the trial\n6. Ability to read, write and understand English sufficiently well to complete study procedures and provide informed consent.\n\nExclusion Criteria:\n\n1. Past history of a primary psychotic or bipolar disorder\n2. Current acute suicidality or significantly elevated risk of suicide as determined by the investigators\n3. Personal history of moderate traumatic brain injury, epilepsy, or other clinically significant neurological illness except tic disorders\n4. A history of pre-eclampsia during the most recent pregnancy if the patient is less than 8 weeks postpartum\n5. Current, moderate to severe alcohol or illicit substance use disorder in the last 3 months, determined by clinical assessment\n6. Women who are currently pregnant. All participants will be asked to use a reasonable birth control method throughout the study period (barrier, oral contraceptives, etc.). We will not administer pregnancy tests.\n7. current psychotic symptoms\n8. A current seizure disorder\n9. active severe major depressive episode as indicated on the Edinburgh Postnatal Depression Scale (greater than or equal to 19).","FEMALE","45 Years",{"count":106,"type":20},15,[23],"The goal of this clinical trial is to learn if accelerated transcranial magnetic stimulation (TMS) is a feasible treatment for obsessive compulsive disorder that worsens or starts within 12 months of childbirth. The main questions it aims to answer are:\n\nIs TMS a tolerable and acceptable treatment for postpartum women with OCD?\n\nDoes TMS improve OCD symptoms in postpartum women?\n\nDoes TMS change connectivity between areas of the brain involved in OCD?\n\nParticipants will:\n\n1. Receive 50 sessions of a type of TMS called continuous theta burst stimulation (cTBS) over the course of two weeks.\n2. Complete clinical assessments before and after TMS, as well as at 1 and 3 months post-treatment\n3. Undergo functional magnetic resonance imaging (fMRI) of the brain before and after TMS",[110],"Postpartum Obsessive Compulsive Disorder",[112,113,114,115,116,117],"obsessive compulsive disorder","ocd","postpartum","peripartum","tms","transcranial magnetic stimulation","NOT_YET_RECRUITING","2026-04-30",{"date":121,"type":37},"2026-05-06",{"date":123,"type":20},"2026-04",{"date":125,"type":20},"2028-06",{"name":43,"class":44},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":15,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":73},"100497073","optimization-of-a-behavioral-intervention-to-increase-physical-activity-in-older-adults-living-with-hiv-100497073","NCT05752500","Optimization of a Behavioral Intervention to Increase Physical Activity in Older Adults Living With HIV","HiActivity","Inclusion Criteria:\n\n1. HIV positive: defined by HIV antibody, detectable HIV RNA in plasma, or a note from the participant's HIV care provider.\n2. Must be on continuous antiretroviral therapy (ART) for \\> 3 months, as assessed via self-report.\n3. Low PA: defined as self-report of \\\u003C 90 minutes of moderate-vigorous PA (MVPA) per week in the previous 3 months AND less than 14 hours per week of sustained walking in the previous 4 weeks.\n4. Medically cleared for moderate PA. If participants report a) a history of cardiovascular disease including known coronary artery disease, peripheral vascular disease, heart failure, or stroke; or b) chest pain, shortness of breath, or dizziness or syncope either at rest or during activity in the past 3 months, then they must have medical clearance by a physician or primary care provider.\n5. Age 50 years or older.\n6. Proficiency in English: sufficient to engage in informed consent, understand assessments and materials provided, and engage and use Fitbit application (all materials provided in English).\n7. Capacity to consent, documented by acceptable answers in a consent \"teach-back\" process.\n8. Score of greater than 16 on the MOCA\n9. Able to ambulate without assistive devices\n10. Ability to use the FitBit application, as demonstrated to study staff.\n\nExclusion Criteria:\n\n* Exclusion Criteria\n\n  1. Medical conditions or physical or neurocognitive limitations that interfere with PA or study participation.\n  2. Hazardous substance use, assessed via a score ≥15 on the Alcohol Use Disorders Identification Test (AUDIT) or ≥6 on the Drug Abuse Screening Test (DAST).","50 Years",{"count":136,"type":20},196,[23],"The goal of this clinical trial is to examine 3 interventions designed to increase physical activity in older adults with HIV. We will examine 3 potential components of an intervention package: physical activity coaching, cognitive behavioral therapy targeted toward common barriers to physical activity such as low motivation or chronic pain, and a Fitbit-based social support intervention. Our primary outcome will be physical activity, defined as steps per day. Results will guide choice of intervention components to be used in an optimized behavioral intervention.",[140,141,142],"Hiv","Physical Inactivity","Aging","2026-03-13",{"date":145,"type":37},"2026-03-17",{"date":147,"type":37},"2023-06-21",{"date":93,"type":20},{"name":43,"class":44},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":172,"locationsCount":45},"100484264","mood-and-thought-process-study-100484264","NCT05585775","Mood and Thought Process Study","Affective Executive Functioning as a Mechanism of Treatments for Depression Symptoms","MAT Process","Inclusion Criteria:\n\n1. Adults 18 years or older\n2. English fluency in order to complete study procedures\n3. Normal vision or corrected to normal vision\n4. QIDS score ≥ 5 and ≤ 15 to include individuals with elevated, but not severe symptoms of depression\n5. No presence of psychotic symptoms that interfere with functioning\n6. No current hazardous alcohol or drug use\n7. No previous experience with mindfulness-based treatment (i.e., enrollment in MBSR or MBCT previously)\n8. No current symptoms of mania indicative of a manic episode\n9. No current cognitive impairment\n10. No history of a formally diagnosed learning disability in reading, intellectual disability or other developmental disorder\n11. No history of a neurologic illness affecting cognition\n12. If on psychiatric medications, no change in medications for at least 4 weeks\n13. If in psychotherapy, no change in therapy status for at least 4 weeks\n\nExclusion Criteria:\n\nExclusion criteria include: (a) presence of psychotic symptoms that interfere with one's ability to function as determined by the SCID-5 Psychotic Screening Module; (b) current hazardous alcohol or drug use as indicated by a score of \\>10 for men and women on the AUDIT and the DUDIT for cannabis use, and \\>6 for men and women on the DUDIT for all other drugs (everything but cannabis), (c) change in psychiatric drug prescription within 4 weeks; (d) started psychotherapy or other psychiatric treatment within the past 4 weeks; (e) current suicide ideation or behavior which requires urgent intervention due to safety concerns; (f) Previous enrollment in MBCT or MBSR; (g) symptoms of mild cognitive impairment as indicated by a score of \\\u003C26 on the MoCA; (h) formally diagnosed learning disability, intellectual disability, or other developmental disorder; (i) history of neurologic illness affecting cognition; (j) current symptoms indicative of a manic episode per the SCID-5 Mood Disorders Module.",{"count":159,"type":20},76,[23],"The primary objective for this project is to test whether affective executive functioning is a mechanism of action of mindfulness-based cognitive therapy and Wellness for Wellbeing. The main questions it aims to answer are:\n\n1. Test the effect of MBCT vs. Wellness for Wellbeing on affective inhibition (i.e., emotionally valenced inhibition as measured via the affective Go\u002FNo Go task) using an RCT.\n2. Test the effect of MBCT vs. Wellness for Wellbeing on (a) affective updating and (b) affective shifting. Outcomes will be measured with the affective n-Back and the affective Internal Switching Task, respectively.\n\n3a) The investigators will examine whether depression symptom severity co-varies with change in affective executive functioning (i.e., affecting inhibition, shifting, and updating) over time. 3b) The investigators will examine whether compliance with treatment protocol (e.g., number of classes attended, amount of home practice) predicts endpoint executive functioning.\n\nParticipants will complete surveys, interviews, and computer tasks, and will be randomized to either Mindfulness-Based Cognitive Therapy or Wellness for Wellbeing.",[163,164,165],"Depression in Remission","Depressive Symptoms","Depression","2025-11-04",{"date":168,"type":37},"2025-11-05",{"date":170,"type":37},"2023-04-06",{"date":41,"type":20},{"name":43,"class":44},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":103,"minAge":53,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":45},"100607935","womens-wellbeing-study-100607935","NCT07195019","Women's Wellbeing Study","Treatments for Improving Mood in Women","Inclusion Criteria:\n\n1. Female\n2. Ages 18-65\n3. Report having experienced interpersonal violence (defined to include all forms throughout the lifespan, confirmed with the Trauma History Questionnaire (THQ\\])\n4. Report being distressed, defined by a score of \\>5 on the Kessler-6 screener\n5. Speak and understand English well enough to understand questionnaires when they are read aloud\n6. Have access to a telephone through owning one, a relative\u002Ffriend, or an agency\n7. Have access to a device that will support use of the video platform we are using to conduct assessments and for home practice yoga video sessions\n\nExclusion Criteria:\n\n1. Inability to be physically active, determined by a score \\>1 on the Physical Activity Readiness Questionnaire (PAR-Q) and physician non-consent of participation\n2. Planned surgery in next 6 months, as this would interfere with study participation\n3. Pregnancy, as yoga should be modified for pregnancy\n\n   Women who meet criteria for the following:\n4. Current mania as determined by the Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND)\n5. Lifetime history of psychotic disorders (DIAMOND)\n6. Current probable severe substance use disorder (DIAMOND)\n7. Current diagnosis of anorexia nervosa or history in past year (DIAMOND)\n8. Moderate or high risk for suicide on the adapted Columbia Suicide Severity Rating Scale screen version-recent (C-SSRS) and\u002For endorsement of suicidal plan\u002Fintent in the past 3 months\n9. Non-stable course of psychiatric treatments (medication, psychotherapy) for the last 8 weeks\n10. Plan to move from the area in the next 6 months, as this may preclude study participation given enrollment timeframes\n11. Self-report of experiencing intimate partner violence currently or within past six months (assessed by the Revised Conflict Tactics Scale 2 \\[R-CTS2\\]), as this would require a different type of intervention\n12. Current weekly yoga practice or current participation in mindfulness-based programming, as these are the study interventions","65 Years",{"count":182,"type":20},48,[23],"Phase 2 is a randomized controlled trial of integrative yoga and mindful self-compassion program vs. women's wellbeing education for women with a history of interpersonal violence exposure and heightened distress.",[186],"Distress, Psychological","2025-09-19",{"date":189,"type":37},"2025-09-26",{"date":191,"type":37},"2025-08-27",{"date":193,"type":20},"2027-05-31",{"name":43,"class":44},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100453116","feasibility-acceptability-and-preliminary-efficacy-of-a-novel-personalized-mobile-intervention-for-suicide---open-trial-2-100453116","NCT05180344","Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide - Open Trial (2)","Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide","Inclusion Criteria:\n\n* Suicidal ideation and\u002For suicidal behavior in the past month verified by the C-SSRS\n* Between the ages of 18 and 26\n* English proficiency\n* Comfortable with smartphone technology\n* Deemed by the treatment team to be stable enough to complete study procedures\n\nExclusion Criteria:\n\n* Current psychotic or manic symptoms severe enough to interfere with study procedures","26 Years",{"count":204,"type":20},10,[23],"The primary aim of this grant is to conduct pilot testing on a novel personalized mobile intervention for suicide - Mobile Application to Prevent Suicide (MAPS) - and to establish feasibility, acceptability, safety, and primary outcomes (i.e., suicidal ideation and behavior; re-hospitalization).",[208,209,210,211],"Suicide","Suicide and Self-harm","Suicide, Attempted","Suicidal Ideation","2025-07-14",{"date":214,"type":37},"2025-07-17",{"date":216,"type":37},"2024-07-25",{"date":218,"type":20},"2025-10-01",{"name":43,"class":44},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":15,"minAge":134,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":73},"100400946","phase-1-repurposing-nucleoside-reverse-transcriptase-inhibitors-for-treatment-of-ad-100400946","NCT04500847","Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD","LINE-AD","Inclusion Criteria:\n\n* Male or female, ages 50-85 years inclusive\n* Intellectually, visually and auditory capable, fluent in, and able to read, the language in which study assessments are administered (e.g. completion of at least six years of regular schooling or sustained employment or equivalent local level of knowledge).\n* Must meet NIA-AA research criteria for MCI and mild dementia due to AD\n* Mini Mental State Exam (MMSE) 15-30 inclusive\n* Clinical Dementia Rating (CDR) 0.5 - 2\n* Must meet a cerebrospinal fluid (CSF) pTau\u002FAβ42 ratio of \\> 0.024\n* Participants must have an appropriate study partner who agrees to participate in the study and who is intellectually, visually, and auditory capable, and fluent in, and able to read, the language in which study assessments are administered. Additionally, the study partner must be capable of and willing to: Accompany the participant to visits that requires the input of the study partner\n* Concurrent treatment with cholinesterase inhibitors and memantine are permitted on a stable dose for at least 60 days prior to baseline.\n\nExclusion Criteria:\n\n* Current medical or neurological condition that might impact cognition or performance on cognitive assessments, e.g., Huntington's disease, Parkinson's disease, syphilis, schizophrenia, bipolar disorder, active major depression, attention deficit\u002F hyperactivity disorder (ADD\u002FADHD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), active seizure disorder, current alcohol\u002Fdrug abuse or dependence, or dependence within the last two years, or history of traumatic brain injury associated with loss of consciousness and ongoing residual transient or permanent neurological signs\u002Fsymptoms including cognitive deficits, and\u002For associated with skull fracture\n* Brain MRI results showing findings unrelated to AD that, in the opinion of the investigator might be a leading cause of future cognitive decline, might pose a risk to the participant, or might confound MRI assessment for safety monitoring\n* Score \"yes\" on item four or item five of the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (eC-SSRS patient-reported outcome), if this ideation occurred in the past six months, or \"yes\" on any item of the Suicidal Behavior section, except for the \"Non-Suicidal Self-Injurious Behavior\" (item is included in the Suicidal Behavior section), if this behavior occurred in the past 2 years prior to screening\n* Use of other investigational drugs prior to screening until:\n\n  * Small molecules: after five half-lives, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer\n  * Biologicals: blood concentration has returned to baseline (or below serological responder threshold) for antibodies induced by active immunotherapy; or five half- lives for monoclonal antibodies or other biologicals\n* Approximately four weeks prior to randomization, the use of any drug or treatment known for the potential to cause major organ system toxicity, i.e. drugs that may require periodic safety monitoring of a specific organ or body fluid. Examples include, but are not limited to clozapine, cancer medical treatment like tamoxifen, systemic immunosuppressive drugs like methotrexate or interferon, or other immunosuppressive biological medicines for rheumatic diseases or multiple sclerosis\n* A positive drug screen, if, in the investigator's opinion, this is due to drug abuse or dependence.\n* Significant ECG findings that are assessed as clinically significant by the investigator (e.g. sustained ventricular tachycardia, significant second or third degree atrioventricular block without a pacemaker, long QT syndrome or clinically meaningful prolonged QT interval).\n* Contraindication to lumbar puncture including use of anti-coagulants, low platelet count, history of back surgery (with the exception of microdiscectomy or laminectomy over one level), signs or symptoms of intracranial pressure, spinal deformities or other spinal conditions that in the judgment of the investigator would preclude a lumbar puncture\n* History of or active hepatitis or HIV infection (based on a positive lab result for HBV and\u002For HIV, to be performed during screening\n* Severe renal impairment\n* Severe hepatic impairment\n* Significant cardiac disease including recent (within six months) myocardial infarction, congestive heart failure or unstable angina\n* Female subjects who are pregnant or currently breastfeeding.","85 Years",{"count":229,"type":20},35,[231],"PHASE1","This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.",[234,235,236],"Alzheimer Disease, Early Onset","Mild Cognitive Impairment","Moderate Dementia","2025-05-01",{"date":239,"type":37},"2025-05-04",{"date":241,"type":37},"2021-12-17",{"date":243,"type":20},"2026-03-31",{"name":43,"class":44},""]